<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04162002</url>
  </required_header>
  <id_info>
    <org_study_id>REST- HAN-2019</org_study_id>
    <nct_id>NCT04162002</nct_id>
  </id_info>
  <brief_title>Restylane® Lyft Filler Injection for Hand Rejuvenation on First Impressions</brief_title>
  <official_title>Effects of Restylane® Lyft Filler Injection for Hand Rejuvenation on First Impressions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DeNova Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Galderma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DeNova Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to determine the effects of Restylane® Lyft Filler injection
      into the back of the hand on first impressions.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2019</start_date>
  <completion_date type="Actual">November 18, 2019</completion_date>
  <primary_completion_date type="Actual">November 18, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The effects of Restylane® Lyft Filler injection into the dorsal hand on first impressions.</measure>
    <time_frame>4 weeks</time_frame>
    <description>Subjects will have a picture of their hand evaluated by third party physicians on the basis of:
Social Skills Positive mood, gets along with others well, friendly 1-10 rating
Academic Performance Intelligent, highly educated, received good grades in school 1-10 rating
Dating Success Dates frequently, lacks dating anxiety 1-10 rating
Occupational Success Good worker, competent, motivated for success, suitable as potential employee 1-10 rating
Attractiveness Pleasing appearance 1-10 rating
Financial Success Has achieved financial success, member of a high social class 1-10 rating
Relationship Success Willingness to compromise, ability to maintain long term friendships 1-10 rating
Athletic Success Excels at athletic skills, plays individual and/or team sports 1-10 rating</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Hand Rejuvination</condition>
  <arm_group>
    <arm_group_label>Restylane® Lyft Filler Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Restylane® Lyft</intervention_name>
    <description>Filler Injection</description>
    <arm_group_label>Restylane® Lyft Filler Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females of ages 28 and above.

          2. Subjects will be required not to have had previous filler fat injections, or other
             cosmetic treatments to their hands within the last 12 months.

          3. Subjects that understand the purpose and aspects of the study, freely sign the consent
             and complete the required treatment and follow up visit. -

        Exclusion Criteria:

          1. Males and females below age of 28.

          2. Subjects who have had previous filler, fat injections, or other cosmetic treatments to
             their hands within the last 12 months.

          3. Subjects who are pregnant or nursing.

          4. Subjects with a known allergy or sensitivity to any component of the study
             ingredients.

          5. Any history of bleeding disorders (iatrogenic or otherwise). This includes persons who
             have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet
             aggregation in the preceding 3 weeks.

          6. Anyone taking aspirin, ibuprofen, St. John's Wort, or high doses of Vitamin E
             supplements in the last 3 weeks.

          7. Subjects with diseases, injuries, or disabilities of the hand, including those with
             autoimmune disease affecting the hand, hand implants, Dupuytren's contracture, history
             of hand tumor, vascular malformations, Raynaud's disease and patients at risk for
             tendon rupture.

          8. Subjects that do not understand the purpose and aspects of the study, do not sign the
             consent and do not complete the required treatment and follow up visit will also be
             excluded. -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>August 1, 2019</study_first_submitted>
  <study_first_submitted_qc>November 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2019</study_first_posted>
  <last_update_submitted>November 18, 2019</last_update_submitted>
  <last_update_submitted_qc>November 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Steven H. Dayan</investigator_full_name>
    <investigator_title>Principal Investigator, Clinical Assistant Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

